ReviewJournal of diabetes and metabolic disorders2022
A Meta-analysis of ADIPOQ rs2241766 polymorphism association with type 2 diabetes.
Review in Journal of diabetes and metabolic disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 10 citations in OpenAlex.
- Association ofGenes · 2024Article
- Potential Association of The Pathogenic Kruppel-like Factor 14 (KLF14) and Adiponectin (ADIPOQ) SNVs with Susceptibility to T2DM.Endocrine, metabolic & immune disorders drug targets · 2024Article
- Cell Therapy and Investigation of the Angiogenesis of Fibroblasts with Collagen Hydrogel on the Healing of Diabetic Wounds.Turkish journal of pharmaceutical sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: There is extensive research on the association between polymorphisms in the adiponectin gene (ADIPOQ) and type 2 diabetes (T2D). The present meta-analytic study explored the association between ADIPOQ rs2241766 polymorphisms and T2D. Metolds: Articles were collected by searching Google Scholar, Scopus, and PubMed electronic databases until 2021. They were searched using a systematic search of original and sensitive English keywords and their equivalent keywords based on the keywords "type 2 diabetes", "ADIPOQ", and "rs2241766". The article selection criteria were based on the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram. Results: The results revealed that there was no bias in this study. Some studies, such as Joshaghani et al. (odds ratio [OR] = 2.18), Hussain et al. (OR = 2.12), Momin (OR = 4.45), and Amal et al. (OR = 1.84), showed an increasing effect of ADIPOQ rs266729 polymorphism on T2D with 95% CI (P ˂ 0.01), while some have shown no significant association between them. Conclusion: The results of this meta-analytic study showed the relationship between ADIPOQ and rs2241766. Also, it was found that Rs2241766 polymorphism and allele increase the risk, and rs2241766 increases the risk of developing T2D (OR = 1.29).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.